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Background: Glucagon like peptide-1 (GLP-1), an incretin hormone, regulates glucose metabolism by inducing
insulin secretion and suppressing glucagon secretion. The aim of the study is to assess the levels of fasting and
post-prandial GLP-1 and their risk for T2DM. A case control study was conducted at the diabetes clinic Sanglah
Hospital Denpasar Bali, involving 40 subjects who were native Indonesian citizens and 18–70 years of age. Twenty
subjects were allocated as the case group (subjects with T2DM) and 20 subjects were allocated as the control group
(subjects with normal glucose tolerance [NGT]). Both fasting intact GLP-1 (FGLP-1) and 60 minutes post-75 gram
glucose loading intact GLP-1 (1hGLP-1) levels were measured.
Results: Both fasting and post-prandial GLP-1 levels were significantly lower in subjects with T2DM than those with
NGT (2.06 ± 0.43 vs. 2.87 ± 0.67 pg/L, p < 0.01; and 2.49 ± 0.60 vs. 3.42 ± 0.85 pg/L, p = 0.02; respectively). Low levels
of FGLP-1 (OR, 13.5; p = 0.001) and 1hGLP-1 (OR, 5.667, p = 0.018), with no response after glucose loading (ΔGLP-1),
were a significant risk for T2DM. According to the ΔGLP-1, there was a tendency of decreasing response of GLP-1
after glucose loading among subjects with T2DM (Δ = 0.43 pg/L) compared to subjects with NGT (Δ = 0.55 pg/L).
Conclusion: From this study it can be concluded that levels of intact GLP-1 are an important risk factor for T2DM
in the Indonesian population.
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Type 2 diabetes mellitus (T2DM) is a metabolic disease.
It is a result of a combination of genetic predisposition,
lifestyle and environment that are considered to be in-
volved in its pathogenesis. Recently it has been widely
known that changes of behavior, ways of life and the en-
vironment are predominant risk factors for T2DM [1].
The prevalence of T2DM in young adults is around 2.8
percent in 2000 and it is projected that the number of
patients will increase from 171 million people in 2000 to
approximately 366 million in 2030 [2]. In Bali, the preva-
lence of diabetes in adults was at 5.9% as reported by
Suastika et al. in 2011 [3].
The concept that gut endocrine stimulates pancreatic
secretion was first hypothesized in 1902. It was considered
a big leap in the understanding of incretins that function as
a regulator of blood glucose through regulation of insulin* Correspondence: ksuas@yahoo.com
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unless otherwise stated.and glucagon secretion [4]. Two gut hormones, glucagon-
like peptide-1 (GLP-1) and glucose dependent insulinotro-
pic polypeptide or gastric inhibitory polypeptide (GIP), have
been shown to act as incretins. GLP-1 has been developed
as the basis of therapy for patients with T2DM. It was re-
ported that in Caucasian patients with T2DM the GLP-1
levels decreased compared to that in normal subjects [5].
The total GLP-1 levels in among non-diabetic Japanese and
Caucasians turned out to be comparable, but the intact
GLP-1 levels was much lower in Japanese compared to
Caucasians [6].
In Indonesia, no data on GLP-1 levels are available
both in normal subjects and subjects with T2DM. Thus,
this study was conducted to assess the GLP-1 levels in
fasting and after glucose loading states and the response
of GLP-1 after glucose loading; and to prove that low
GLP-1 levels was a risk factor of T2DM in the Indonesian
population.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 2 Risk of low FGLP-1, 1hGLP-1, and ΔGLP-1 levels
for T2DM




12 (60%) 2 (10%) 13,5 (2.434-74.867) 0.001
Normal GLP-1
(≥2.21 pg/L)




10 (50%) 3 (15%) 5.667 (1.254-25.606) 0.018
Normal 1hGLP-1
(≥2.57 pg/L)




2 (10%) 2 (10%) 1.00 (0.127-7.893) 1.0
Normal ΔGLP-1
(≥0.029 pg/L)
18 (90%) 18 (90%)
T2DM, type 2 diabetes mellitus; NGT, normal glucose tolerance; FGLP-1, fasting
GLP-1; 1hGLP-1, 1 h after glucose loading GLP-1; DGLP-1, responses of GLP-1
after loading.
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A case–control study was conducted at the Diabetes
Clinic Sanglah Hospital, Denpasar, Bali, Indonesia,
during the period of February to April 2014. Twenty
cases (subjects with T2DM) and 20 subjects with nor-
mal glucose tolerance (NGT), aged 18–70 years, were
enrolled in the study as the control group. All subjects
were native Indonesian citizens. The diagnosis of dia-
betes was confirmed based on the criteria of ADA
(2014) [7]. The levels of intact GLP-1 were measured
in fasting (FGLP-1, at least 8 hours) and 60 minutes
post-loading standard 75 gram anhydrous glucose
(1hGLP-1) states. The levels of plasma intact GLP-1
were measured by the EIA kit, Cat.No.: RSCYK 160R,
Bio Vendor Research and Diagnostic Products. Low
level of GLP-1 was confirmed if the level of FGLP-1
was <2.21 pg/L; 1hGLP-1 was <2.57 pg/L; and the
response or difference of fasting and post-prandial
(ΔGLP-1) was <0.029 pg/L. The values were deter-
mined by calculation of “mean-1SD” for each value
(fasting, post-prandial and Δ) in subject with NGT
or control group. This study protocol was approved
by the Research Ethics Committee Faculty of Medi-
cine, Udayana University, Denpasar, before the study
was conducted (registration no.790/UN.4.2/Litbang/
2013). Written informed consent was obtained from
all participants.
Statistical tests used to analyze the data in the study
included a descriptive presentation, a Mann–Whitney
test, cross-tab (χ2 test and prevalence risk or odds ratio
[OR]), with significant value confirmed at P < 0.05.Results
The mean age of the subjects was 56.85 ± 5.71 years
(case, 57.05 ± 5.77 years and control, 56.65 ± 5.79 years,
respectively). Body mass index in subjects with T2DM
was higher than subjects with NGT, 28.94 ± 1.96 and
24.79 ± 3.07, respectively (P < 0.01).The mean of FGLP-1,
1hGLP-1, and ΔGLP-1 are seen in Table 1. Both FGLP-1
and 1hGLP-1 levels were lower significantly in subjectsTable 1 Levels of GLP-1 among subjects with T2DM and
normoglycemia
Variable T2DM (n = 20) NGT (n = 20) P
Fasting Plasma Sugar (mg/dl) 194.70 ± 10.50 82.60 ± 5.42 <0.01
Prandial Plasma Sugar (mg/dl) 315.35 ± 26.25 133.90 ± 8.55 <0.01
FGLP-1 (pg/L) 2.06 ± 0.43 2.87 ± 0.67 <0.01
1hGLP-1 (pg/L) 2.49 ± 0.60 3.42 ± 0.85 0.002
ΔGLP-1 (pg/L) 0.43 ± 0.36 0.55 ± 0.52 0.715
T2DM, type 2 diabetes mellitus; NGT, normal glucose tolerance; FGLP-1, fasting
GLP-1; 1hGLP-1, 1 hour after glucose loading GLP-1; ΔGLP-1, responses of
GLP-1 after loading.with T2DM than those with NGT (2.06 ± 0.43 vs. 2.87 ±
0.67 pg/L, P < 0.01; and 2.49 ± 0.60 vs. 3.42 ± 0.85 pg/L,
P = 0.02; respectively).
Low levels of FGLP-1 and 1hGLP-1 were more frequently
found in subjects with T2DM than in subjects with
NGT (60% vs. 10%, P = 0.001 and 50% vs. 15%, P =
0.018, respectively). Low levels of FGLP-1 (OR, 13.5;
P = 0.001) and 1hGLP-1 (OR, 5.667, P = 0.018) were
significantly a risk factor for T2DM, but not for ΔGLP-
1 (Table 2). Although it has not been proven that
ΔGLP-1 is a risk factor for T2DM, by looking at the re-
sponse of GLP-1 after glucose loading, there seemed to
be a tendency of decreasing response of GLP-1 among
subjects with T2DM (Δ = 0.43 pg/L) compared to sub-
jects with NGT (Δ = 0.55 pg/L) (Figure 1).Figure 1 Response of GLP-1 after 75 g glucose-loading T2DM,
type 2 diabetes mellitus; NGT, normal glucose tolerance; FGLP-1,
fasting GLP-1; 1hGLP-1, 1 h after glucose loading GLP-1.
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This study revealed that the levels of GLP-1 in fasting
and post-prandial states in subjects with T2DM were
lower than in subjects with NGT (2.06 vs. 2.87 pg/L and
2.49 vs. 3.42 pg/L, respectively). Velasquez-Mieyer et al.
in 2008 reported that African-Americans exhibited lower
GLP-1active levels at 15 min after OGTT than Caucasians
(3.75 ± 0.63 vs. 9.5 ± 4.5 pmol/L, P = 0.03) [8]. Levels of
fasting GLP-1active in African-Americans was lower
than in Caucasians (3.31 ± 1.14 vs. 6.67 ± 3.84 pmol/L)
but the difference was not statistically significant. As
summarized by Seino et al. in 2010, the intact GLP-1
level was lower in Japanese than Caucasians [6]. Gen-
etic or race background might influence the levels of
GLP-1 since the levels widely vary among different
races. In Japanese, fasting levels of total and intact
GLP-1 were lower in patients with T2DM than the
control group (15.5 ± 1.7 vs. 15.7 ± 1.0; and 0.2 ± 0.1
vs. 0.7 ± 0.2 pM, respectively) [9]. In Chinese adults
the levels of total fasting GLP-1, 2hGLP-1 decreased
significantly in prediabetes (impaired fasting glycemia
[IFG] and impaired glucose tolerance [IGT]) and T2DM
compared to normal glucose tolerance (NGT) and isolated
IFG or IGT [10]. A similar finding showed Caucasian
subjects with T2DM had decreased GLP-1 levels com-
pared to the control subjects (23.8 ± 3.17 vs. 76.4 ±
4.47 pg/mL, P < 0.001) [11]. From the two review articles it
can be summarized that low level of GLP-1 in T2DM is
caused by impaired secretion of GLP-1 and accelerated
metabolism of GLP-1. Low level or activity of GLP-1 in
T2DM decrease an oral glucose dependent insulin secre-
tion [12,13].
Low levels of FGLP-1 (OR, 13.5) and 1hGLP-1 (OR,
5.667) seen in this study were significant risk factors
for T2DM. Although the ΔGLP-1 was not a significant
risk factor for T2DM, it revealed a trend of decreased
response of intact GLP-1 after glucose loading among
subjects with T2DM (0.43 pg/L) compared to subjects
with NGT (0.55 pg/L). Two hours total GLP-1 incre-
ments (ΔGLP-1) following OGTT reduced signifi-
cantly in T2DM (4.26 ± 6.27 pmol/L) group compared
to NGT (12.37 ± 10.05 pmol/L) and isolated IFG
(10.37 ± 9.82 pmol/L) or IGT (9.79 ± 10.50 pmol/L)
groups [10]. A similar result was also reported by
Vilsboll et al. in 2003 that there was decreased GLP-1
responses after large meals in T2DM patients com-
pared to healthy subjects [14].
Since there were differences in the type of GLP-1
(total or intact/active), method and unit GLP-1 measure-
ment used in several different studies, there has been
difficulty in comparing the absolute value between this
study and other studies. However, it can be concluded
that there was similarity in the findings that the levels of
FGLP-1 and response after meal or glucose loading ofGLP-1 were reduced in subjects with T2DM compared
to subjects with NGT.
Conclusion
Both FGLP-1 and 1hGLP-1 levels were lower in subjects
with T2DM than in subjects with NGT. Low level of
GLP-1 was an important risk factor of T2DM.
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